Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

92
The BAK Portfolio: Canadian Weed Is Legal And The Green Rush Has Begun

2018-07-17 seekingalpha
An escalating trade war and a tepid rebound in Canadian cannabis stocks left the portfolio running in the red for the second quarter in a row.
LXX TAP GRWG TWMJF KHRNF MICWF WEED RTI APHQF CGC LXRP

2
Lexaria Announces 2018 AGM Results and Corporate Update

2018-07-03 accesswire
KELOWNA, BC / ACCESSWIRE / July 3, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces the results of the 2018 Annual General and Special Meeting. All motions were passed.
LXX LXRP

5
Lexaria Files New Patent Application for Enhancement of Delivery of Lipophilic Agents Across the Blood-Brain Barrier and Methods for Treating Central Nervous System Disorders

2018-06-29 accesswire
KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / June 29, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") a drug delivery platform innovator, announces it has filed an important new patent application with the United States Patent and Trademark Office ("USPTO") for innovation in treatment options related to central nervous system disease or disorders including viral infection, cancer, neurodegenerative disorders, ADHD, anxiety, depression, OCD, schizophrenia, Alzheimer's, Huntington's, Parkinson's, neuropathic pain and more.
LXX LXRP

30
Canadian Legalization: What's Next For Cannabis Stocks?

2018-06-21 seekingalpha
On June 19, 2018, the Canadian Senate passed The Cannabis Act 52 to 29. The rest of the approval process will be completed before the end of the week.
SNNVF KHRNF ACBFF RTI DTK CGC GSK LXX TWMJF ACB WEED RDDTF OGRMF OGI LXRP

5
Lexaria Bioscience Corp. Structures Nicotine & Pharmaceutical Subsidiaries

2018-05-31 accesswire
KELOWNA, BC / ACCESSWIRE / May 31, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, announces that, subject to ongoing legal and tax analysis, it intends to create two wholly-owned subsidiaries that will respectively hold the intellectual property (''IP'') related to, in the case of the first subsidiary, the improved processing and combustion-free delivery of nicotine and nicotine analogs and, in the case of the second subsidiary, delivery of non-steroidal anti-inflammatory drugs (''NSAIDs''), phosphodiesterase (''PDE5'') inhibitors and other active pharmaceutical ingredients.
LXX LXRP

5
Lexaria Announces Exercises of Existing Warrants, Enters Consulting Agreement

2018-05-28 accesswire
KELOWNA, B.C. / ACCESSWIRE / May 28, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) announces warrant transactions.
LXX LXRP

5
Lexaria Bioscience Corp. Receives New Granted Patents

2018-05-23 accesswire
KELOWNA, BC / ACCESSWIRE / May 23, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received notifications that it has received two new US patents granted and additionally expects three new Australian patents granted on or before August 17th.
LXX LXRP

174
30 Marijuana Stocks to Buy as the Future Turns Green

2018-05-14 investorplace
When it comes to cannabis, we’ve come a long way since former President Bill Clinton denied ever inhaling. With the previous presidential administration’s frankness on the matter, marijuana has become more blasé. Naturally, marijuana stocks have also increased in popularity, where we have more choices today than was previously thought possible.
IGCIW MNTR IGC ACBFF DTK HEMP TRTCD CANN LXX CVSI CBIS SRNA LDSYF MJNA APH AMMJ ACAN ABBV SMG LXRP INQD MDCL MSC.H CARA RMHB IIPR.PRA POTN ACB IIPR IMLFF KAYS PKPH TRTC GRNH ABBV APHQF

5
Lexaria Announces LOI with Hill Street Beverage Co. for Cannabis Infused Alcohol-Free Beer and Wine

2018-04-27 accesswire
KELOWNA, BC / ACCESSWIRE / April 27, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces that it has entered a Letter of Intent (the "LOI") with Hill Street Beverage Co. to license DehydraTECH TM, on a semi exclusive basis to produce a line of cannabis infused alcohol-free beers and wines for Canadian distribution, following regulatory approval.
LXX LXRP

5
Lexaria Enters Definitive License Agreement with California Cannabis Beverage Manufacturer

2018-04-25 accesswire
KELOWNA, BC / ACCESSWIRE / April 25, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") a drug delivery platform innovator, announces it has entered a definitive technology licensing agreement (the "Agreement") with GP Holdings LLC. ("GP") whereby Lexaria is providing its patented DehydraTECHTM technology to empower next-generation performance in high absorption, fast-acting cannabis-infused beverages to be developed and sold in California.
LXX LXRP

5
Lexaria Announces Human Clinical Study on CBD Absorption Underway

2018-04-23 accesswire
KELOWNA, BC / ACCESSWIRE / April 23, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, is pleased to announce that it has commenced a clinical study in Europe to evaluate the cardiovascular and cognitive health effects of Lexaria's high absorption TurboCBD™ capsules.
LXX LXRP

5
Lexaria Achieves Significant Breakthrough in Alternative Nicotine Delivery Technology

2018-04-17 accesswire
KELOWNA, BC / ACCESSWIRE / April 17, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to announce positive topline results upon completion of its first ingestible nicotine in vivo (animal) absorption study. Lexaria is pursuing the use of its patented DehydraTECHTM technology as a possible new nicotine delivery method, an edible dose absorbed through the gastrointestinal tract, with potential both as a nicotine replacement therapy as well as an alternative product format for regular tobacco users.
LXX LXRP

5
Lexaria Bioscience Corp. Receives New U.S. Patent Allowance for Cannabinoid Delivery and Updates Its Expanding Patent Portfolio

2018-04-11 accesswire
KELOWNA, BC / ACCESSWIRE / April 11, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received another new Notice of Allowance from the United States Patent and Trademark Office ("USPTO") providing claims that protect processes for making specific compositions of matter for enhanced cannabinoid delivery utilizing its DehydraTECH™ technology.
LXX LXRP

5
Lexaria Bioscience Corp. Receives New U.S. Patent Allowance for "Composition of Matter" Cannabinoid Delivery

2018-03-22 accesswire
KELOWNA, BC / ACCESSWIRE / March 22, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received a new Notice of Allowance from the United States Patent and Trademark Office ("USPTO") providing for "composition of matter" claims that protect the specific combination of substances which enable improved taste and bioabsorption properties of its DehydraTECH™ technology for the delivery of cannabinoids.
LXX LXRP

5
Lexaria Files New Patent Application for Enhanced Transdermal Delivery System

2018-03-20 accesswire
KELOWNA, BC / ACCESSWIRE / March 20, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, is pleased to announce it has filed a new patent application with the United States Patent and Trademark Office (''USPTO'') for use of DehydraTECHTM to improve the speed and quantity of absorption of active pharmaceutical ingredients (''API'') through the skin.
LXX LXRP

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to CNSX:LXX / Lexaria Bioscience Corp. on message board site Silicon Investor.

LEXON INC. (LXXN:BB) LXXI
CLXX(CELLEX BIOSCIENCES)